The success of mRNA-based COVID-19 vaccines has created a significant level of interest in this versatile biomolecule for disease prevention and treatment. While production of these vaccines took place in record time, critical decisions must be made when developing novel mRNA applications to ensure manufacturability, reproducibility, and safety.
This webinar will explore foundational elements of the mRNA manufacturing workflow and strategies to design the right facilities to ensure success. Topics include collaborative approaches to ensure access to high-quality raw materials, application of advanced technologies for manufacturing, options for facility design, and key considerations when leveraging a contract development and manufacturing partner.
In this webinar, you will learn:
- Therapeutic potential of mRNA: COVID-19 and beyond
- How mRNA manufacturing workflows and facility design have a significant impact on reproducibility and performance
- Amptec capabilities to accelerate mRNA development and manufacturing
Speakers
Nargisse El Hajjami, Ph.D. Eng.
MilliporeSigma
Senior Consultant
Nargisse El Hajjami, Ph.D. Eng. is a senior consultant for novel modalities and the global lead for mRNA technology within our bioprocessing strategy operationalization group. Nargisse is a molecular microbiologist and bioprocess expert with 11 years of experience combining scientific research, process development, and biomanufacturing engineering. In her current role, Nargisse focuses on novel modalities business development by leading strategic initiatives, supporting go-to-market strategies, providing directions to operationalize the business strategy, as well as supporting customers to build, grow, and optimize their manufacturing processes.
Shiksha Mantri, Ph.D.
MilliporeSigma
Global Marketing Manager, RNA Solutions
Shiksha Mantri holds a Ph.D. in chemical biology from the University of Oxford, U.K., and did her postdoc at ETH Zurich, Switzerland. She joined MilliporeSigma as the global technical product manager for synthetic lipids, where she was responsible for managing the lipids portfolio and custom manufacturing businesses. She continues to support the top industry players and young start-ups in the fields of RNA delivery and vaccines as the global marketing manager for RNA solutions.
Pharma and biopharma manufacturing
- mRNA
Duration:1h
Language:English
Session 1:presented July 8, 2021
To continue reading please sign in or create an account.
Don't Have An Account?